In adults suffering from post-COVID complications is neurofeedback therapy effective, when comparing conditions before and after the intervention, in reducing the severity of these complications?

Charles University0 个研究点目标入组 17 人开始时间: 2022年4月29日最近更新: 2022年10月17日

试验速览

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35895740/ (added 28/07/2022)

•1. Age 18-65 years
•2. A positive history of SARS-CoV-2 infection confirmed by a positive antigen/reverse transcription polymerase chain reaction (RT-PCR)/antibody test
•3. At least one of the following symptoms: insomnia, headaches/migraines, dizziness, seizures, fatigue, depression, and anxiety that were not present prior to SARS-CoV-2 infection
•4. The specific symptoms should have been present or persisted for at least 3 months after confirmed SARS-CoV-2 infection and should not have been attributable to any other neurological disease prior to COVID-19
•5. Being free of neurological/systemic health problems prior to SARS-CoV-2
•6. Being medication-free (or medically stable in type and dosage of the drug for at least 3 months prior to neurofeedback experiment)

•1. Younger than 18 years
•2. No positive anamnesis of SARS-CoV-2 infection confirmed by positive antigen/RT-PCR/antibody test
•3. Absence of post-COVID complications
•4. The presence of neurological/systemic disorders prior to SARS-CoV-2 infection

发起方

Charles University